. | Placebo (N = 113) . | Supplementation (N = 118) . | 1 Versus 2 . | ||||
---|---|---|---|---|---|---|---|
. | n . | Md . | (IQR, Range) . | n . | Md . | (IQR, Range) . | P . |
Height (cm) | 92 | 177 | (174–183; 160–196) | 85 | 180 | (176–184; 166–193) | .06 |
Body mass (kg) | 91 | 74 | (69–82; 51–142) | 85 | 76 | (69–85; 58–109) | .43 |
BMI | 91 | 24 | (22–26; 18–41) | 85 | 24 | (21–26; 17–33) | .97 |
Aerobic fitness (km) | 93 | 2.5 | (2.2–2.6; 1.2–3.0) | 83 | 2.5 | (2.3–2.6; 0.6–3.0) | .79 |
S-25(OH)D (nmol/L) | 96 | 55 | (45–66; 24–123) | 88 | 55 | (47–65; 18–89) | .57 |
Cathelicidin (ng/ml) | 96 | 38.7 | (31.0–50.0; 12–731) | 88 | 40.0 | (32.9–58.5;19–743) | .29 |
. | Placebo (N = 113) . | Supplementation (N = 118) . | 1 Versus 2 . | ||||
---|---|---|---|---|---|---|---|
. | n . | Md . | (IQR, Range) . | n . | Md . | (IQR, Range) . | P . |
Height (cm) | 92 | 177 | (174–183; 160–196) | 85 | 180 | (176–184; 166–193) | .06 |
Body mass (kg) | 91 | 74 | (69–82; 51–142) | 85 | 76 | (69–85; 58–109) | .43 |
BMI | 91 | 24 | (22–26; 18–41) | 85 | 24 | (21–26; 17–33) | .97 |
Aerobic fitness (km) | 93 | 2.5 | (2.2–2.6; 1.2–3.0) | 83 | 2.5 | (2.3–2.6; 0.6–3.0) | .79 |
S-25(OH)D (nmol/L) | 96 | 55 | (45–66; 24–123) | 88 | 55 | (47–65; 18–89) | .57 |
Cathelicidin (ng/ml) | 96 | 38.7 | (31.0–50.0; 12–731) | 88 | 40.0 | (32.9–58.5;19–743) | .29 |
Abbreviations: BMI, body mass index; IQR, interquartile range; Md, median; S-25(OH)D, Serum 25(OH)D.
. | Placebo (N = 113) . | Supplementation (N = 118) . | 1 Versus 2 . | ||||
---|---|---|---|---|---|---|---|
. | n . | Md . | (IQR, Range) . | n . | Md . | (IQR, Range) . | P . |
Height (cm) | 92 | 177 | (174–183; 160–196) | 85 | 180 | (176–184; 166–193) | .06 |
Body mass (kg) | 91 | 74 | (69–82; 51–142) | 85 | 76 | (69–85; 58–109) | .43 |
BMI | 91 | 24 | (22–26; 18–41) | 85 | 24 | (21–26; 17–33) | .97 |
Aerobic fitness (km) | 93 | 2.5 | (2.2–2.6; 1.2–3.0) | 83 | 2.5 | (2.3–2.6; 0.6–3.0) | .79 |
S-25(OH)D (nmol/L) | 96 | 55 | (45–66; 24–123) | 88 | 55 | (47–65; 18–89) | .57 |
Cathelicidin (ng/ml) | 96 | 38.7 | (31.0–50.0; 12–731) | 88 | 40.0 | (32.9–58.5;19–743) | .29 |
. | Placebo (N = 113) . | Supplementation (N = 118) . | 1 Versus 2 . | ||||
---|---|---|---|---|---|---|---|
. | n . | Md . | (IQR, Range) . | n . | Md . | (IQR, Range) . | P . |
Height (cm) | 92 | 177 | (174–183; 160–196) | 85 | 180 | (176–184; 166–193) | .06 |
Body mass (kg) | 91 | 74 | (69–82; 51–142) | 85 | 76 | (69–85; 58–109) | .43 |
BMI | 91 | 24 | (22–26; 18–41) | 85 | 24 | (21–26; 17–33) | .97 |
Aerobic fitness (km) | 93 | 2.5 | (2.2–2.6; 1.2–3.0) | 83 | 2.5 | (2.3–2.6; 0.6–3.0) | .79 |
S-25(OH)D (nmol/L) | 96 | 55 | (45–66; 24–123) | 88 | 55 | (47–65; 18–89) | .57 |
Cathelicidin (ng/ml) | 96 | 38.7 | (31.0–50.0; 12–731) | 88 | 40.0 | (32.9–58.5;19–743) | .29 |
Abbreviations: BMI, body mass index; IQR, interquartile range; Md, median; S-25(OH)D, Serum 25(OH)D.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.